S

Sage Therapeutics
D

SAGE

7.07000
USD
0.10
(1.43%)
مغلق
حجم التداول
68,803
الربح لكل سهم
-4
العائد الربحي
-
P/E
-1
حجم السوق
432,494,969
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CLLS
    -0.03000
    (-1.98%)
    1.48500 USD
    C
    CRSP
    0.260
    (0.65%)
    40.520 USD
    E
    EDIT
    -0.03000
    (-2.40%)
    1.22000 USD
    F
    FOLD
    0.07000
    (0.75%)
    9.43000 USD
    Q
    QURE
    -0.190
    (-1.33%)
    14.050 USD
    R
    RCKT
    0.095
    (0.93%)
    10.300 USD
    S
    SGEN
    0
    (0%)
    0 USD
    المزيد
الأخبار
المقالات

العنوان: Sage Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.